COST-EFFECTIVENESS OF SECOND-LINE VASOPRESSORS FOR THE TREATMENT OF SEPTIC SHOCK

被引：0
|
作者：
Lam, Simon [1 ]
Barreto, Erin [2 ]
Scott, Rachael [3 ]
Kashani, Kianoush [3 ]
Khanna, Ashish [4 ]
Bauer, Seth [5 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] St Marys Hosp, Mayo Clin, Rochester, MN USA
[3] Mayo Clin, Rochester, MN USA
[4] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA
[5] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA
来源：
CRITICAL CARE MEDICINE | 2020年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
1630
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Cost-Effectiveness of Second-Line Therapies in Adult Patients with Chronic Immune Thrombocytopenia
    Goshua, George
    Sinha, Pranay
    Pischel, Lauren
    Lee, Alfred Ian
    Cuker, Adam
    BLOOD, 2021, 138
  • [32] Second-line treatment of metastatic gastric cancer in the era of predictive biomarkers: A cost-effectiveness analysis.
    Lauren, Brianna
    Silver, Elisabeth
    Ingram, Myles
    Oh, Aaron
    Kumble, Lindsay
    Ostvar, Sassan
    Laszkowska, Monika
    Chu, Jacqueline N.
    Manji, Gulam Abbas
    Neugut, Alfred I.
    Hur, Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] COST-EFFECTIVENESS OF ESCITALOPRAM VERSUS VENLAFAXINE IN SECOND-LINE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN SWEDEN
    Despiegel, N.
    Danchenko, N.
    Maman, K.
    VALUE IN HEALTH, 2009, 12 (03) : A177 - A177
  • [34] Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer
    Levy-Piedbois, C
    Durand-Zaleski, I
    Juhel, H
    Schmitt, C
    Bellanger, A
    Piedbois, P
    ANNALS OF ONCOLOGY, 2000, 11 (02) : 157 - 161
  • [35] A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer
    Holmes, J
    Dunlop, D
    Hemmett, L
    Sharplin, P
    Bose, U
    PHARMACOECONOMICS, 2004, 22 (09) : 581 - 589
  • [36] A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer
    Jeremy Holmes
    David Dunlop
    Lindsay Hemmett
    Peter Sharplin
    Uday Bose
    PharmacoEconomics, 2004, 22 : 581 - 589
  • [37] COST-EFFECTIVENESS IN THE SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE US
    Graham, C.
    Knox, H.
    Hess, L. M.
    Jen, M.
    Carter, Cuyun G.
    Chandrawansa, K.
    Boye, M.
    VALUE IN HEALTH, 2015, 18 (07) : A457 - A458
  • [38] Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden
    Srivastava, Tushar
    Prabhu, Vimalanand S.
    Li, Haojie
    Xu, Ruifeng
    Zarabi, Natalie
    Zhong, Yichen
    Pellissier, James M.
    Perini, Rodolfo F.
    de Wit, Ronald
    Mamtani, Ronac
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (05): : 663 - 670
  • [39] Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review
    Jiejin Zhu
    Ying Zhou
    Qingyu Li
    Gang Wang
    Advances in Therapy, 2023, 40 : 4216 - 4235
  • [40] Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review
    Zhu, Jiejin
    Zhou, Ying
    Li, Qingyu
    Wang, Gang
    ADVANCES IN THERAPY, 2023, 40 (10) : 4216 - 4235
12345